Prescription Orthopedic Drugs Global Market Report 2025

The prescription orthopedic drugs market size has grown strongly in recent years. It will grow from $48.41 billion in 2024 to $51.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period was driven by the rising prevalence of musculoskeletal disorders, an increasing geriatric population, greater awareness of osteoporosis treatments, expanded healthcare access in developing regions, and a surge in sports-related injuries worldwide.

The prescription orthopedic drugs market size is expected to see strong growth in the next few years. It will grow to $65.32 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period is expected to be driven by the rising demand for biologics, an increasing geriatric population, expanded healthcare access in emerging markets, a growing prevalence of chronic musculoskeletal disorders, and increased investments in orthopedic drug research and development. Key trends include advancements in targeted biologics, the adoption of regenerative medicine therapies, personalized drug formulations, innovations in minimally invasive delivery methods, enhanced drug efficacy through gene therapy, developments in injectable formulations, and the integration of artificial intelligence in drug development and clinical decision-making.

The growing prevalence of musculoskeletal disorders is expected to propel the expansion of the prescription orthopedic drugs market. Musculoskeletal disorders (MSDs) encompass injuries and conditions that impact the movement and function of the body's musculoskeletal system, including muscles, tendons, ligaments, nerves, and joints, leading to pain and restricted mobility. The rising occurrence of these disorders can be attributed to factors such as aging, occupational activities involving repetitive motions and awkward postures, sedentary lifestyles, inadequate nutrition, and genetic predispositions. Prescription orthopedic drugs play a crucial role in managing musculoskeletal disorders by alleviating pain, reducing inflammation, and promoting the healing process, ultimately improving mobility and overall quality of life. For example, in March 2023, the Office for Health Improvement and Disparities, a UK-based government department for public health, reported that 17.6% of individuals aged 16 and older in 2022 had a long-term musculoskeletal (MSK) condition, such as arthritis or persistent back or joint problems, an increase from 17% in 2021. Additionally, in July 2022, the World Health Organization, a Switzerland-based intergovernmental organization, estimated that approximately 1.71 billion people worldwide suffer from musculoskeletal disorders. As a result, the increasing prevalence of musculoskeletal disorders is fueling the growth of the prescription orthopedic drugs market.

Leading companies in the prescription orthopedic drugs sector are prioritizing the expansion of indications for their drugs to extend market reach, enhance patient outcomes, and address unmet medical needs across various orthopedic conditions. For instance, in January 2023, Heron Therapeutics Inc., a US-based biotechnology company, received FDA approval for the extended use of ZYNRELEF (bupivacaine and meloxicam) in soft tissue and orthopedic procedures, including foot and ankle surgeries. This extended-release formulation is specifically designed to provide prolonged pain relief for up to 72 hours, minimizing or eliminating the need for opioid medications post-surgery. The expanded indication now encompasses a wider range of orthopedic and soft tissue procedures, broadening its use in clinical settings. The drug’s innovative dual-drug combination delivers both local anesthetic and anti-inflammatory effects, offering a comprehensive solution for managing post-operative pain while improving patient outcomes.

In April 2024, ProMed Pharma LLC, a US-based pharmaceutical company, acquired SpineThera Inc. for an undisclosed sum. Through this acquisition, ProMed aims to strengthen its drug delivery capabilities by utilizing SpineThera’s expertise in extended-release injectable therapies, particularly in pain management for musculoskeletal and orthopedic conditions. SpineThera Inc. is a US-based company specializing in the development of extended-release injectable therapies for treating musculoskeletal conditions, including back pain and orthopedic disorders.

Major players in the prescription orthopedic drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck KGaA, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Allergan plc, Penardo Biotech Pvt. Ltd., Horizon Therapeutics plc.

North America was the largest region in the prescription orthopedic drugs market in 2024. The regions covered in prescription orthopedic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prescription orthopedic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prescription orthopedic drugs are medications specifically prescribed to treat musculoskeletal conditions affecting bones, joints, muscles, and ligaments. These drugs help relieve pain, reduce inflammation, and promote healing in orthopedic injuries and disorders such as arthritis, fractures, and tendonitis.

The primary types of prescription orthopedic drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and others. NSAIDs are a class of medications that alleviate pain, inflammation, and fever by inhibiting enzymes responsible for prostaglandin production. These drugs are commonly used to manage conditions such as osteoarthritis, rheumatoid arthritis, and osteoporosis. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The prescription orthopedic drugs market research report is one of a series of new reports that provides prescription orthopedic drugs market statistics, including the prescription orthopedic drugs industry's global market size, regional shares, competitors with a prescription orthopedic drugs market share, detailed prescription orthopedic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription orthopedic drugs industry. This prescription orthopedic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prescription orthopedic drugs market consists of sales of products such as bisphosphonates, creams, gels, or patches, calcium and vitamin D supplements, and analgesics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.